Figure 5.

Effect of WAY 161503 on the expression of Fos in GAD-positive DRN neurones. (a) Drug treatments were vehicle-vehicle, vehicle-WAY 161503 (3 mg kg⁻¹), SB 242084 (1.0 mg kg⁻¹)-vehicle and SB 242084 (1.0 mg kg⁻¹)-WAY 161503 (3 mg kg⁻¹). Data (n=6) are mean±s.e.m. Note that WAY 161503 increased the number of Fos/GAD double-labelled cells and that this effect was reduced by pre-treatment with SB 242084. ^**P<0.001 versus vehicle–vehicle (one way ANOVA with Dunnett's post hoc test). ^#P<0.05 versus vehicle–WAY 161503 (one-way ANOVA with Bonferroni's post hoc test). (b) Photomicrographs showing cells double labelled (arrows) with Fos and GAD immunoreactivity in the DRN of rats administered one the following drug treatments: vehicle–vehicle, SB 242084 (1.0 mg kg⁻¹)–vehicle, SB 242084 (1.0 mg kg⁻¹)–WAY 161503 (3 mg kg⁻¹), vehicle–WAY 161503 (3 mg kg⁻¹). Images at × 40 magnification.